| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8039451 | ANACOR PHARMS INC | Boron-containing small molecules |
Jun, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9682092 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(3 years from now) | |
| US8501712 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Feb, 2027
(3 years from now) | |
|
US8501712 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(3 years from now) | |
|
US9682092 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Aug, 2027
(3 years from now) | |
|
US8039451 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules |
Dec, 2029
(6 years from now) | |
| US8168614 | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jan, 2030
(6 years from now) | |
|
US8168614 (Pediatric) | ANACOR PHARMS INC | Boron-containing small molecules as anti-inflammatory agents |
Jul, 2030
(6 years from now) | |
Eucrisa is owned by Anacor Pharms Inc.
Eucrisa contains Crisaborole.
Eucrisa has a total of 8 drug patents out of which 0 drug patents have expired.
Eucrisa was authorised for market use on 14 December, 2016.
Eucrisa is available in ointment;topical dosage forms.
Eucrisa can be used as method of treating mild to moderate atopic dermatitis..
The generics of Eucrisa are possible to be released after 20 July, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Mar 23, 2023 |
| Pediatric Exclusivity (PED) | Sep 23, 2023 |
Drugs and Companies using CRISABOROLE ingredient
Market Authorisation Date: 14 December, 2016
Treatment: Method of treating mild to moderate atopic dermatitis.
Dosage: OINTMENT;TOPICAL
EUCRISA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic